These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 19815482)

  • 1. Dose escalation using a hypofractionated, intensity-modulated radiation therapy boost for localized prostate cancer: preliminary results addressing concerns of high or low alpha/beta ratio.
    Shridhar R; Bolton S; Joiner MC; Forman JD
    Clin Genitourin Cancer; 2009 Oct; 7(3):E52-7. PubMed ID: 19815482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypofractionated boost to the dominant tumor region with intensity modulated stereotactic radiotherapy for prostate cancer: a sequential dose escalation pilot study.
    Miralbell R; Mollà M; Rouzaud M; Hidalgo A; Toscas JI; Lozano J; Sanz S; Ares C; Jorcano S; Linero D; Escudé L
    Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):50-7. PubMed ID: 19910135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypofractionated accelerated radiotherapy using concomitant intensity-modulated radiotherapy boost technique for localized high-risk prostate cancer: acute toxicity results.
    Lim TS; Cheung PC; Loblaw DA; Morton G; Sixel KE; Pang G; Basran P; Zhang L; Tirona R; Szumacher E; Danjoux C; Choo R; Thomas G
    Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):85-92. PubMed ID: 18355982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensity-modulated radiotherapy as primary therapy for prostate cancer: report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion.
    Fonteyne V; Villeirs G; Speleers B; De Neve W; De Wagter C; Lumen N; De Meerleer G
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):799-807. PubMed ID: 18407430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer.
    Fonteyne V; De Gersem W; De Neve W; Jacobs F; Lumen N; Vandecasteele K; Villeirs G; De Meerleer G
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1013-20. PubMed ID: 19386427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer.
    Alicikus ZA; Yamada Y; Zhang Z; Pei X; Hunt M; Kollmeier M; Cox B; Zelefsky MJ
    Cancer; 2011 Apr; 117(7):1429-37. PubMed ID: 21425143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiation dose escalation for localized prostate cancer: intensity-modulated radiotherapy versus permanent transperineal brachytherapy.
    Wong WW; Vora SA; Schild SE; Ezzell GA; Andrews PE; Ferrigni RG; Swanson SK
    Cancer; 2009 Dec; 115(23):5596-606. PubMed ID: 19670452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypofractionated intensity-modulated radiotherapy (70 gy at 2.5 Gy per fraction) for localized prostate cancer: long-term outcomes.
    Kupelian PA; Thakkar VV; Khuntia D; Reddy CA; Klein EA; Mahadevan A
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1463-8. PubMed ID: 16169683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypofractionated intensity-modulated radiotherapy for carcinoma of the prostate: analysis of toxicity.
    Coote JH; Wylie JP; Cowan RA; Logue JP; Swindell R; Livsey JE
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1121-7. PubMed ID: 19131179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer.
    Zelefsky MJ; Chan H; Hunt M; Yamada Y; Shippy AM; Amols H
    J Urol; 2006 Oct; 176(4 Pt 1):1415-9. PubMed ID: 16952647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of hypofractionated image-guided intensity-modulated radiotherapy for localized prostate adenocarcinoma.
    Martin JM; Rosewall T; Bayley A; Bristow R; Chung P; Crook J; Gospodarowicz M; McLean M; Ménard C; Milosevic M; Warde P; Catton C
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1084-9. PubMed ID: 17606331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of pretreatment prostate volume on severe acute genitourinary toxicity in prostate cancer patients treated with intensity-modulated radiation therapy.
    Aizer AA; Anderson NS; Oh SC; Yu JB; McKeon AM; Decker RH; Peschel RE
    Int J Radiat Oncol Biol Phys; 2011 Feb; 79(2):379-84. PubMed ID: 20452135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preliminary results in prostate cancer patients treated with high-dose-rate brachytherapy and intensity modulated radiation therapy (IMRT) vs. IMRT alone.
    Wilder RB; Barme GA; Gilbert RF; Holevas RE; Kobashi LI; Reed RR; Solomon RS; Walter NL; Chittenden L; Mesa AV; Agustin JK; Lizarde J; Macedo JC; Ravera J; Tokita KM
    Brachytherapy; 2010; 9(4):341-8. PubMed ID: 19853534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer.
    Al-Mamgani A; Heemsbergen WD; Peeters ST; Lebesque JV
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):685-91. PubMed ID: 18718725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensity-modulated radiation therapy: supportive data for prostate cancer.
    Cahlon O; Hunt M; Zelefsky MJ
    Semin Radiat Oncol; 2008 Jan; 18(1):48-57. PubMed ID: 18082588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.
    Zelefsky MJ; Fuks Z; Hunt M; Lee HJ; Lombardi D; Ling CC; Reuter VE; Venkatraman ES; Leibel SA
    J Urol; 2001 Sep; 166(3):876-81. PubMed ID: 11490237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I/II study of a five-fraction hypofractionated accelerated radiotherapy treatment for low-risk localised prostate cancer: early results of pHART3.
    Tang CI; Loblaw DA; Cheung P; Holden L; Morton G; Basran PS; Tirona R; Cardoso M; Pang G; Gardner S; Cesta A
    Clin Oncol (R Coll Radiol); 2008 Dec; 20(10):729-37. PubMed ID: 18838256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of toxicity in patients with high risk prostate cancer treated with intensity-modulated pelvic radiation therapy and simultaneous integrated dose escalation to prostate area.
    Arcangeli S; Saracino B; Petrongari MG; Gomellini S; Marzi S; Landoni V; Gallucci M; Sperduti I; Arcangeli G
    Radiother Oncol; 2007 Aug; 84(2):148-55. PubMed ID: 17692416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The rationale behind hypofractionated high-dose intensity-modulated radiotherapy in patients with localized prostate cancer: short review.
    Szychot E; Brodkiewicz A; Peregud-Pogorzelski J
    Ann Acad Med Stetin; 2012; 58(1):45-8. PubMed ID: 23547394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rectal dose constraints for intensity modulated radiation therapy of the prostate.
    Swanson GP; Stathakis S
    Am J Clin Oncol; 2011 Apr; 34(2):188-95. PubMed ID: 20622649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.